Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD

  title={Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD},
  author={R. Buhl and Donald D Banerji},
  booktitle={International journal of chronic obstructive pulmonary disease},
Bronchodilators are central in the symptomatic management of chronic obstructive pulmonary disease (COPD). Long-acting muscarinic antagonists (LAMAs) and long-acting β(2)-agonists (LABAs) are the main classes of long-acting bronchodilators. To date, tiotropium is the only once-daily LAMA available for the treatment of COPD. Glycopyrronium is a novel LAMA, currently in development for COPD. Phase II studies have shown that glycopyrronium 50 μg once daily provides clinically significant 24-hour… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 9 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 22 extracted citations


Publications referenced by this paper.
Showing 1-10 of 58 references

Efficacy and safety of NVA237 versus placebo and tiotropium in patients with moderate-to-severe COPD over 52 weeks: The GLOW2 study

  • E Kerwin, J Hébert, P Korenblat
  • Eur Respir J. July
  • 2012
Highly Influential
10 Excerpts

A novel model-based approach for dose determination of NVA237 in COPD

  • H Arievich, T Overend, D Renard
  • Respir Res. Submitted
  • 2012

New Drugs Online

  • UK Medicines Informatio
  • Glycopyrrolate; 2012. Available from: http://www…
  • 2012
1 Excerpt

Symptoms, consultations and comorbidities in real-world COPD patients classified by the GOLD 2011 strategy

  • V Higgins, S Broomfield, M. Small
  • Abstract accepted at the COPD8 International…
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…